With the disease becoming more and more common in the United States, researchers have been hard at work determining the best possible treatment options.

Omecamtiv mecarbil, a cardiac myosin activator being manufactured by Amgen and Cytokinetics to treat heart failure with reduced ejection fraction, has been granted a Fast Track designation by the FDA.

The algorithm, developed as part of a collaboration with Mayo Clinic, received Breakthrough Device designation back in December 2019.

Rheumatoid arthritis is associated with a greater risk of heart failure, according to new findings published in the Journal of the American Heart Association. The risk increases even more when patients have higher levels of C-reactive protein, a telltale sign of severe inflammation.  

Mavacamten has demonstrated value as a treatment option for patients with obstructive hypertrophic cardiomyopathy (HCM), according to results from the EXPLORER-HCM phase III clinical trial.

The FDA has approved a new treatment option, Farxiga oral tablets, for adult heart failure patients with reduced ejection fraction.

Transcatheter edge-to-edge tricuspid valve repair (TTVR) is an effective treatment option for patients with severe tricuspid regurgitation (TR), according to a new study published in JACC: Heart Failure.

Key chemotherapy treatments are known to have a negative impact on cardiovascular health, even leading to heart failure (HF) in some patients.

Liraglutide, a common medication used to treat type 2 diabetes (T2D), is safe to use for heart failure (HF) patients, according to new findings published in the Journal of the American College of Cardiology.

Long-term daily exposure to air pollution carrying fine particulate matter poses a significant risk of all-cause mortality for people with heart failure (HF).

Heart patients with implanted left ventricular assist devices are more likely to both attempt and succeed in committing suicide than other chronically ill patients, according to a study out of France.

Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?